phenylacetic acid has been researched along with Prostatic Neoplasms in 11 studies
phenylacetic acid : A monocarboxylic acid that is toluene in which one of the hydrogens of the methyl group has been replaced by a carboxy group.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The refractoriness of prostate cancer to androgen suppression is the landmark of clinically aggressive disease." | 1.29 | Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. ( Basolo, F; Danesi, R; Del Tacca, M; Myers, CE; Nardini, D; Samid, D, 1996) |
| "Exposure of prostate cancer cell lines to PB reduces their DNA synthesis, leads to fragmentation of genomic DNA, and causes 50-60% of cells to undergo apoptosis." | 1.29 | Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. ( Ayyagari, SR; Campbell, PA; Carducci, MA; Chan-Tack, KM; Nelson, JB; Nelson, WG; Simons, JW; Sweatt, WH, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (72.73) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Samid, D | 4 |
| Shack, S | 2 |
| Myers, CE | 4 |
| Esquenet, M | 1 |
| Swinnen, JV | 1 |
| Heyns, W | 1 |
| Verhoeven, G | 1 |
| Danesi, R | 1 |
| Nardini, D | 1 |
| Basolo, F | 1 |
| Del Tacca, M | 1 |
| Walls, R | 1 |
| Thibault, A | 1 |
| Liu, L | 2 |
| Wood, C | 1 |
| Kozlowski, JM | 1 |
| Figg, WD | 1 |
| Sampson, ML | 1 |
| Elin, RJ | 1 |
| Hudgins, WR | 1 |
| Prasanna, P | 1 |
| Carducci, MA | 2 |
| Nelson, JB | 1 |
| Chan-Tack, KM | 1 |
| Ayyagari, SR | 1 |
| Sweatt, WH | 1 |
| Campbell, PA | 1 |
| Nelson, WG | 1 |
| Simons, JW | 1 |
| Walczak, J | 1 |
| Wood, H | 1 |
| Wilding, G | 1 |
| Williams, T | 1 |
| Bishop, CW | 1 |
| Carducci, M | 1 |
| Artemov, D | 1 |
| Solaiyappan, M | 1 |
| Bhujwalla, ZM | 1 |
| Gilbert, J | 1 |
| Bowling, MK | 1 |
| Noe, D | 1 |
| Eisenberger, MA | 1 |
| Sinibaldi, V | 1 |
| Zabelina, Y | 1 |
| Chen, TL | 1 |
| Grochow, LB | 1 |
| Donehower, RC | 1 |
| Smigel, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Progressive or Recurrent CNS Malignancy[NCT00006450] | Phase 2 | 120 participants | Interventional | 2000-11-30 | Completed | ||
| Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy[NCT00001565] | Phase 1 | 35 participants | Interventional | 1996-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for phenylacetic acid and Prostatic Neoplasms
| Article | Year |
|---|---|
Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers.
Topics: Adult; Antimetabolites, Antineoplastic; Brain Neoplasms; Cell Differentiation; Clinical Trials, Phas | 1997 |
Differentiating agents and nontoxic therapies.
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Fatty Acids; Humans; Male; Phenylacetates; P | 1999 |
1 trial available for phenylacetic acid and Prostatic Neoplasms
| Article | Year |
|---|---|
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.
Topics: Adult; Antineoplastic Agents; Chromatography, High Pressure Liquid; Disorders of Excessive Somnolenc | 2001 |
8 other studies available for phenylacetic acid and Prostatic Neoplasms
| Article | Year |
|---|---|
Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.
Topics: Animals; Cell Division; Cell Survival; DNA Replication; Female; Glutamine; HLA-A3 Antigen; Humans; M | 1993 |
Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.
Topics: Animals; Cell Division; Cell Survival; DNA Replication; Female; Glutamine; HLA-A3 Antigen; Humans; M | 1993 |
Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.
Topics: Animals; Cell Division; Cell Survival; DNA Replication; Female; Glutamine; HLA-A3 Antigen; Humans; M | 1993 |
Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.
Topics: Animals; Cell Division; Cell Survival; DNA Replication; Female; Glutamine; HLA-A3 Antigen; Humans; M | 1993 |
Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate.
Topics: Androgens; Antimetabolites, Antineoplastic; Calcitriol; Cell Differentiation; Cell Division; Humans; | 1996 |
Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Genes, ras; Humans; Male; Phenylacetates; | 1996 |
The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells.
Topics: Animals; Carcinoma; Cell Differentiation; Cell Division; Dose-Response Relationship, Drug; Gene Expr | 1996 |
Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate.
Topics: Animals; Antineoplastic Agents; Apoptosis; Butyric Acid; DNA; Humans; Male; Phenylacetates; Phenylbu | 1996 |
Prostate cancer prevention strategies using antiproliferative or differentiating agents.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cel | 2001 |
Magnetic resonance pharmacoangiography to detect and predict chemotherapy delivery to solid tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carbon Isotopes; Contrast Media; Drug Mo | 2001 |
Non-toxic drug being tested to treat cancer and anemias.
Topics: Anemia; Brain Neoplasms; Glutamine; Humans; Male; Phenylacetates; Phenylbutyrates; Prostatic Neoplas | 1992 |